// App-Quantinova.ai

13117 : Incorporation of High-Sensitivity Troponin Along With the AHA/ACC Cholesterol Guidelines for Improved Risk Stratification and Targeted PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease

Researchers

Presenter

  • Nicholas A Marston

Principal Investigators

  • Kazuma Oyama

  • Minao Tang

  • Petr Jarolim

  • Peter S Sever

  • Anthony C Keech

  • Armando Lira Pineda

  • Huei Wang

  • Robert Giugliano

  • Marc S Sabatine

  • David A Morrow

Medical Centers

  • Brigham & Women's Hospital, Boston, MA

  • BRIGHAM AND WOMENS HOSPITAL, Boston, MA

  • IMPERIAL COLLEGE, London, United Kingdom

  • NHMRC CLINICAL TRIALS CENTRE, Camperdown Sydney, Australia

  • AMGEN, Thousand Oaks, CA

  • AMGEN, Newbury Park, CA

  • TIMI Study Group, Boston, MA

Locations

  • United States

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Coronary Artery Disease

  • Angina

  • Stroke

Biomarkers

  • Acetyl-CoA carboxylase

  • Cholesterol

  • Proprotein convertase subtilisin/kexin type 9

Drug/Treatment

  • Evolocumab

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved